These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22612303)

  • 1. Meta-analysis: IL-28B genotype and sustained viral clearance in HCV genotype 1 patients.
    Rangnekar AS; Fontana RJ
    Aliment Pharmacol Ther; 2012 Jul; 36(2):104-14. PubMed ID: 22612303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
    Chen Y; Xu HX; Wang LJ; Liu XX; Mahato RI; Zhao YR
    Aliment Pharmacol Ther; 2012 Jul; 36(2):91-103. PubMed ID: 22591106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis.
    Rangnekar AS; Fontana RJ
    J Viral Hepat; 2013 Jun; 20(6):377-84. PubMed ID: 23647954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
    Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
    Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis.
    Liu T; Sha K; Yang L; Wang Y; Zhang L; Liu X; Yang F
    PLoS One; 2014; 9(3):e91316. PubMed ID: 24642705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
    Huang CF; Yeh ML; Hsieh MH; Hsieh MY; Lin ZY; Chen SC; Wang LY; Huang JF; Juo SH; Lin YC; Dai CY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2013 Sep; 28(9):1515-20. PubMed ID: 23560893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
    Thompson AJ; Muir AJ; Sulkowski MS; Ge D; Fellay J; Shianna KV; Urban T; Afdhal NH; Jacobson IM; Esteban R; Poordad F; Lawitz EJ; McCone J; Shiffman ML; Galler GW; Lee WM; Reindollar R; King JW; Kwo PY; Ghalib RH; Freilich B; Nyberg LM; Zeuzem S; Poynard T; Vock DM; Pieper KS; Patel K; Tillmann HL; Noviello S; Koury K; Pedicone LD; Brass CA; Albrecht JK; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Jul; 139(1):120-9.e18. PubMed ID: 20399780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-28B genotypes determine response to pegylated-interferon plus ribavirin therapy in patients with hepatitis C virus infection.
    Osaki R; Nishimura T; Shioya M; Takeuchi T; Okumura Y; Nakahara T; Bamba S; Nakajo S; Fujiyama Y; Andoh A
    Mol Med Rep; 2012 Feb; 5(2):525-8. PubMed ID: 22052088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of
    Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
    World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study.
    Peng CY; Chen TH; Lim YP; Tsai FJ; Lin WY; Liao WL; Wan L
    BMC Gastroenterol; 2014 Jun; 14():113. PubMed ID: 24969847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL28B polymorphism -- predictive factor of HCV infected genotype 1 individuals to treatment response and management of therapy.
    Ioniţă-Radu F; Raşcanu A; Cheiab B
    Rom J Intern Med; 2011; 49(2):99-104. PubMed ID: 22303600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A; Ruiz-Valderas R; Jimenez-Jimenez L; Abad-Molina C; Gutierrez-Valencia A; Viciana P; Lopez-Cortes LF
    J Viral Hepat; 2014 Mar; 21(3):178-88. PubMed ID: 24438679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study.
    Hu CC; Lin CL; Chang LC; Chien CH; Chen LW; Liu CJ; Chien RN
    BMC Infect Dis; 2015 Mar; 15():156. PubMed ID: 25888020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment efficacy of pegylated interferon plus ribavirin therapy in chronic hepatitis C patients with mixed genotype 1/2 infection.
    Huang CI; Huang CF; Huang JF; Dai CY; Yeh ML; Hsieh MY; Lin ZY; Chen SC; Wang LY; Yu ML; Chuang WL
    J Gastroenterol Hepatol; 2014 May; 29(5):1012-8. PubMed ID: 24325201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High frequencies of a favorable IL-28B rs8099917 polymorphism and the clinical implications in patients with HCV in one multiracial area of Taiwan.
    Cheng CH; Lin CC; Chen HL; Lin IT; Wu CH; Lee YK; Wong MW; Bair MJ
    Kaohsiung J Med Sci; 2017 Oct; 33(10):510-515. PubMed ID: 28962822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.
    Zheng H; Li M; Chi B; Wu XX; Wang J; Liu DW
    Clin Res Hepatol Gastroenterol; 2015 Oct; 39(5):576-83. PubMed ID: 25769643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
    De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
    Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.